AstraZeneca Tagrisso chemo combo cuts risk of lung cancer progression
Roland Magnusson/iStock Editorial via Getty Images AstraZeneca (Nasdaq: AZNAddition to chemotherapy, Tagrisso said, helped improve progression-free survival (PFS) in patients with a type of non-small cell lung cancer (NSCLC) in a phase…
